Peficitinib hydrobromide

Peficitinib hydrobromide (marketed as Smartflap) is an oral Janus kinase (JAK) inhibitor approved mainly in Japan and South Korea for treating moderate-to-severe rheumatoid arthritis (RA) in patients with inadequate responses to conventional therapies. It reduces joint pain and inflammation, and is used to treat adults, either as monotherapy or in combination with other DMARDs. It is grouped under the following drug class(es): Immunosuppressants. Its therapeutic use is listed as anti-inflammatories and antirheumatic agents. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Smyraf (TN) and ASP015K hydrobromide. Its PubChem CID is 67998300.

CAS No 1353219-05-2
Molecular Formula C18H23BrN4O2
Molecular Weight 407.3 g/mol
Synonyms 4-[[(1S,3R)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide;hydrobromide

Frequently Asked Questions